179 related articles for article (PubMed ID: 25001652)
1. If you have an active vagus nerve, cancer stage may no longer be important.
Gidron Y; De Couck M; De Greve J
J Biol Regul Homeost Agents; 2014; 28(2):195-201. PubMed ID: 25001652
[TBL] [Abstract][Full Text] [Related]
2. The relationship between vagal nerve activity and clinical outcomes in prostate and non-small cell lung cancer patients.
De Couck M; van Brummelen D; Schallier D; De Grève J; Gidron Y
Oncol Rep; 2013 Nov; 30(5):2435-41. PubMed ID: 24026706
[TBL] [Abstract][Full Text] [Related]
3. Norms of vagal nerve activity, indexed by Heart Rate Variability, in cancer patients.
De Couck M; Gidron Y
Cancer Epidemiol; 2013 Oct; 37(5):737-41. PubMed ID: 23725879
[TBL] [Abstract][Full Text] [Related]
4. The relationship between heart rate variability and time-course of carcinoembryonic antigen in colorectal cancer.
Mouton C; Ronson A; Razavi D; Delhaye F; Kupper N; Paesmans M; Moreau M; Nogaret JM; Hendlisz A; Gidron Y
Auton Neurosci; 2012 Jan; 166(1-2):96-9. PubMed ID: 22070982
[TBL] [Abstract][Full Text] [Related]
5. Type I collagen biomarkers in the diagnosis of bone metastases in breast cancer, lung cancer, urinary bladder cancer and prostate cancer. Comparison to CEA, CA 15-3, PSA and bone scintigraphy.
Zissimopoulos A; Stellos K; Matthaios D; Petrakis G; Parmenopoulou V; Babatsikou F; Matthaiou E; Theodosiadou E; Hountis P; Koutis C
J BUON; 2009; 14(3):463-72. PubMed ID: 19810140
[TBL] [Abstract][Full Text] [Related]
6. Value of tumor markers in diagnosing and monitoring colorectal cancer and strategies for further improvement: analysis of 130 cases.
Chen C; Chen LQ; Yang GL; Li Y
Ai Zheng; 2007 Nov; 26(11):1221-6. PubMed ID: 17991322
[TBL] [Abstract][Full Text] [Related]
7. Prognostic significance of multiple molecular markers for patients with stage II colorectal cancer undergoing curative resection.
Uen YH; Lin SR; Wu DC; Su YC; Wu JY; Cheng TL; Chi CW; Wang JY
Ann Surg; 2007 Dec; 246(6):1040-6. PubMed ID: 18043108
[TBL] [Abstract][Full Text] [Related]
8. Tumour volume is an independent predictor of prostate-specific antigen recurrence in patients undergoing radical prostatectomy for clinically localized prostate cancer.
Nelson BA; Shappell SB; Chang SS; Wells N; Farnham SB; Smith JA; Cookson MS
BJU Int; 2006 Jun; 97(6):1169-72. PubMed ID: 16686706
[TBL] [Abstract][Full Text] [Related]
9. Increased CYFRA 21-1 and CEA levels are negative predictors of outcome in p-stage I NSCLC.
Muley T; Dienemann H; Ebert W
Anticancer Res; 2003; 23(5b):4085-93. PubMed ID: 14666606
[TBL] [Abstract][Full Text] [Related]
10. Serum tumor markers in colorectal cancer staging, grading, and follow-up.
Plebani M; De Paoli M; Basso D; Roveroni G; Giacomini A; Galeotti F; Corsini A
J Surg Oncol; 1996 Aug; 62(4):239-44. PubMed ID: 8691835
[TBL] [Abstract][Full Text] [Related]
11. Vagal nerve activity predicts overall survival in metastatic pancreatic cancer, mediated by inflammation.
De Couck M; Maréchal R; Moorthamers S; Van Laethem JL; Gidron Y
Cancer Epidemiol; 2016 Feb; 40():47-51. PubMed ID: 26618335
[TBL] [Abstract][Full Text] [Related]
12. The source of pretreatment serum prostate-specific antigen in clinically localized prostate cancer--T, N, or M?
Zagars GK; Kavadi VS; Pollack A; von Eschenbach AC; Sands ME
Int J Radiat Oncol Biol Phys; 1995 Apr; 32(1):21-32. PubMed ID: 7536722
[TBL] [Abstract][Full Text] [Related]
13. Pathological and biochemical outcomes after radical prostatectomy in men with low-risk prostate cancer meeting the Prostate Cancer International: Active Surveillance criteria.
Mitsuzuka K; Narita S; Koie T; Kaiho Y; Tsuchiya N; Yoneyama T; Kakoi N; Kawamura S; Tochigi T; Habuchi T; Ohyama C; Arai Y
BJU Int; 2013 May; 111(6):914-20. PubMed ID: 23320782
[TBL] [Abstract][Full Text] [Related]
14. Identification of Cystatin SN as a novel tumor marker for colorectal cancer.
Yoneda K; Iida H; Endo H; Hosono K; Akiyama T; Takahashi H; Inamori M; Abe Y; Yoneda M; Fujita K; Kato S; Nozaki Y; Ichikawa Y; Uozaki H; Fukayama M; Shimamura T; Kodama T; Aburatani H; Miyazawa C; Ishii K; Hosomi N; Sagara M; Takahashi M; Ike H; Saito H; Kusakabe A; Nakajima A
Int J Oncol; 2009 Jul; 35(1):33-40. PubMed ID: 19513549
[TBL] [Abstract][Full Text] [Related]
15. Community compliance with carcinoembryonic antigen: follow-up of patients with colorectal cancer.
Spratlin JL; Hui D; Hanson J; Butts C; Au HJ
Clin Colorectal Cancer; 2008 Mar; 7(2):118-25. PubMed ID: 18501071
[TBL] [Abstract][Full Text] [Related]
16. CEA in activated macrophages. New diagnostic possibilities for tumor markers in early colorectal cancer.
Japink D; Leers MP; Sosef MN; Nap M
Anticancer Res; 2009 Aug; 29(8):3245-51. PubMed ID: 19661342
[TBL] [Abstract][Full Text] [Related]
17. Serum insulin level, disease stage, prostate specific antigen (PSA) and Gleason score in prostate cancer.
Lehrer S; Diamond EJ; Stagger S; Stone NN; Stock RG
Br J Cancer; 2002 Sep; 87(7):726-8. PubMed ID: 12232754
[TBL] [Abstract][Full Text] [Related]
18. Inflammation-based prognostic system predicts postoperative survival of colorectal cancer patients with a normal preoperative serum level of carcinoembryonic antigen.
Ishizuka M; Nagata H; Takagi K; Iwasaki Y; Kubota K
Ann Surg Oncol; 2012 Oct; 19(11):3422-31. PubMed ID: 22576063
[TBL] [Abstract][Full Text] [Related]
19. Expression profile of prostate-specific antigen messenger RNA assessed by in situ hybridization is a novel prognostic marker for patients with untreated prostate cancer.
Tsurusaki T; Koji T; Sakai H; Kanetake H; Saito Y
Clin Cancer Res; 1998 Sep; 4(9):2187-94. PubMed ID: 9748138
[TBL] [Abstract][Full Text] [Related]
20. Clinical validity of tissue carcinoembryonic antigen expression as ancillary to serum carcinoembryonic antigen concentration in patients curatively resected for colorectal cancer.
Park JW; Chang HJ; Kim BC; Yeo HY; Kim DY
Colorectal Dis; 2013 Sep; 15(9):e503-11. PubMed ID: 23711333
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
